Monument Therapeutics Ltd.. (4/22/21). "Press Release: Change of Director – Monument Therapeutics Is Pleased to Announce that Richard Bungay Will Join the Board as a Director with Immediate Effect".

	Organisation	Monument Therapeutics Ltd.
	Organisation 2	Diurnal Ltd.
	Group	Diurnal Group plc
	Product	personalised medicine / precision medicine
	Product 2	biomarker
	Person	Bungay, Richard (Imophoron 202302 CEO formerly Glide Pharma + Verona Pharma + Chroma Therapeutics + Celltech)

Mr. Bungay has over 25 years’ experience in corporate roles with R&D-based companies within the biotechnology and pharmaceutical sector, including as CFO of both public and private companies, with a particular focus on financing, investor relations and business development. Richard is currently CFO of Diurnal Group plc, the AIM quoted specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases. He is also a Non-executive Director of Cambridge Cognition Holdings plc.

Prior to that, Richard was CFO and Chief Operating Officer of Mereo BioPharma Group plc, a biopharmaceutical company focused on rare and specialty diseases. Richard’s other experience includes being CFO of Glide Technologies, a device and development company focused on solid dose formulations of therapeutics and vaccines, and CFO of Verona Pharma plc, a drug development company focused on first-in-class medicines to treat respiratory diseases.

Richard qualified as a Chartered Accountant with Deloitte in 1993.

Record changed: 2023-06-05